StreetInsider.com News Articles

Alnylam Pharmaceuticals (ALNY) PT Lowered to $455 at H.C. Wainwright

Wed, 05 Aug 2026 06:37:37 -0400

H.C. Wainwright analyst Patrick Trucchio lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $455.00 (from $485.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $315 at Truist Securities

Tue, 04 Aug 2026 07:09:12 -0400

Truist Securities analyst Danielle Brill lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $315.00 (from $410.00) while maintaining a Buy rating.

Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy

Mon, 03 Aug 2026 07:20:49 -0400

Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.

The analyst comments "ALNY shares are -35% since early July on a series of events that have called LT growth potential for the TTR franchise into question. Our TTR modeling exercise (see within note) suggests shares trade near a bear case NPV with no credit assigned to pipeline/collaboration programs. Although a ‘cheap’ stock is not always a reason to buy, what excites us here is the compelling risk/reward opportunity within ALNY’s pipeline. We believe H2 pipeline updates can position ALNY

Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy

Mon, 03 Aug 2026 07:20:49 -0400

Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.

Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy

Mon, 03 Aug 2026 07:20:49 -0400

Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.

Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy

Mon, 03 Aug 2026 07:20:49 -0400

Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $450 at Barclays

Mon, 03 Aug 2026 06:39:10 -0400

Barclays analyst Eliana Merle lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $450.00 (from $527.00) while maintaining a Overweight rating.

Alnylam Pharma. (ALNY) PT Lowered; RBC Capital: 'Tough Update But Stock Reaction Looks Overdone'

Fri, 31 Jul 2026 10:04:20 -0400

(Updated - July 31, 2026 10:04 AM EDT)

RBC Capital analyst Luca Issi lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $350.00 (from $445.00) while maintaining an Outperform rating.

The analyst commented: "Tough Update But Stock Reaction Looks Overdone And We See Fundamental Upside From Here; ALNY reported 2Q and while Amvuttra was just a modest miss ($1,012m vs $1,053m consensus), the company did lower the annual TTR guide (from $4.4-4.7 to $4.2-4.5b) as they acknowledged for the first time that with the benefit of hindsight, the initial few Qs of the launch benefited from meaningful pent-up demand (from second

Alnylam Pharma. (ALNY) PT Lowered; RBC Capital: 'Tough Update But Stock Reaction Looks Overdone'

Fri, 31 Jul 2026 10:04:20 -0400

(Updated - July 31, 2026 10:04 AM EDT)

RBC Capital analyst Luca Issi lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $350.00 (from $445.00) while maintaining an Outperform rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $375 at JPMorgan

Fri, 31 Jul 2026 09:20:17 -0400

JPMorgan analyst Jessica Fye lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $375.00 (from $400.00) while maintaining a Overweight rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $316 at Wells Fargo

Fri, 31 Jul 2026 08:35:37 -0400

Wells Fargo analyst Derek Archila lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $316.00 (from $377.00) while maintaining a Equal Weight rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Oppenheimer

Fri, 31 Jul 2026 08:11:46 -0400

Oppenheimer analyst Kostas Biliouris lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $350.00 (from $500.00) while maintaining a Outperform rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $318 at Stifel

Fri, 31 Jul 2026 08:08:56 -0400

Stifel analyst Paul Matteis lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $318.00 (from $444.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $300 at Morgan Stanley

Fri, 31 Jul 2026 08:00:26 -0400

Morgan Stanley analyst Andrew Galler lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $300.00 (from $400.00) while maintaining a Equalweight rating.

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Fri, 31 Jul 2026 06:41:25 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $485.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "AMVUTTRA 2Q26 growth driven by first-line new patient starts as second-line inflow normalizes; we view the share reaction as overdone. On July 30, Alnylam reported 2Q26 net product revenues of approximately $1,172 million, up 74% YoY, with TTR net product revenues of $1,030 million, up 89% YoY, both below our estimates and consensus. The company also lowered full-year 2026 TTR guidance to $4,200 million to $4,500 million from $4,400 million to $4,700 million, implying 2H26 TTR revenues of $2,259 million

Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30

Thu, 30 Jul 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260730/26839345.html

Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30

Thu, 30 Jul 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260730/26839345.html

Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance

Thu, 30 Jul 2026 08:09:30 -0400

Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $1.84, $0.24 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.32 billion.

GUIDANCE:

Alnylam Pharma sees FY2026 revenue of $4.2-4.5 billion, versus the consensus of $5.61 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance

Thu, 30 Jul 2026 08:09:30 -0400

GUIDANCE:

Alnylam Pharma sees FY2026 revenue of $4.2-4.5 billion, versus the consensus of $5.61 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 30

Thu, 30 Jul 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260730/26839318.html

Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 30

Thu, 30 Jul 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260730/26839318.html

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Thu, 30 Jul 2026 08:00:00 -0400

− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) –

− Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared with 2025 at Revised Midpoint) –

− Presented New Data from HELIOS-B at Heart Failure 2026 Demonstrating Vutrisiran's Consistent Clinical Benefit Across Patient Populations –

− Advanced Pipeline with Phase 2 Initiations of ALN-6400 in Von Willebrand Disease and Mivelsiran in Down Syndrome-Associated

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Thu, 30 Jul 2026 08:00:00 -0400

− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) –
− Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared with 2025 at Revised Midpoint) –
− Presented New Data from HELIOS-B at Heart Failure 2026 Demonstrating Vutrisiran's Consistent Clinical Benefit Across Patient Populations –
− Advanced Pipeline with Phase 2 Initiations of ALN-6400 in Von Willebrand Disease and Mivelsiran in Down Syndrome-Associated

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Thu, 30 Jul 2026 08:00:00 -0400

− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) –
− Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared with 2025 at Revised Midpoint) –
− Presented New Data from HELIOS-B at Heart Failure 2026 Demonstrating Vutrisiran's Consistent Clinical Benefit Across Patient Populations –
− Advanced Pipeline with Phase 2 Initiations of ALN-6400 in Von Willebrand Disease and Mivelsiran in Down Syndrome-Associated

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Thu, 30 Jul 2026 08:00:00 -0400

− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) –
− Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared with 2025 at Revised Midpoint) –
− Presented New Data from HELIOS-B at Heart Failure 2026 Demonstrating Vutrisiran's Consistent Clinical Benefit Across Patient Populations –
− Advanced Pipeline with Phase 2 Initiations of ALN-6400 in Von Willebrand Disease and Mivelsiran in Down Syndrome-Associated